124 related articles for article (PubMed ID: 37820579)
1. Releasing the brake: CTLA-4 loss turbocharges CAR T cells.
Schelker RC; Gattinoni L
Immunity; 2023 Oct; 56(10):2180-2182. PubMed ID: 37820579
[TBL] [Abstract][Full Text] [Related]
2. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.
Agarwal S; Aznar MA; Rech AJ; Good CR; Kuramitsu S; Da T; Gohil M; Chen L; Hong SA; Ravikumar P; Rennels AK; Salas-Mckee J; Kong W; Ruella M; Davis MM; Plesa G; Fraietta JA; Porter DL; Young RM; June CH
Immunity; 2023 Oct; 56(10):2388-2407.e9. PubMed ID: 37776850
[TBL] [Abstract][Full Text] [Related]
3. Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies.
Lin S; Cheng L; Ye W; Li S; Zheng D; Qin L; Wu Q; Long Y; Lin S; Wang S; Huang G; Li P; Yao Y; Sun X
Front Immunol; 2021; 12():642528. PubMed ID: 33868277
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
[TBL] [Abstract][Full Text] [Related]
5. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.
Shin JH; Park HB; Oh YM; Lim DP; Lee JE; Seo HH; Lee SJ; Eom HS; Kim IH; Lee SH; Choi K
Blood; 2012 Jun; 119(24):5678-87. PubMed ID: 22538857
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of CTLA-4, CD28, VDR, and CD45 mRNA in T cells of patients with Hashimoto's thyroiditis - a pilot study.
Tokić S; Štefanić M; Karner I; Glavaš-Obrovac L
Endokrynol Pol; 2017; 68(3):274-828. PubMed ID: 28660994
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
Condomines M; Arnason J; Benjamin R; Gunset G; Plotkin J; Sadelain M
PLoS One; 2015; 10(6):e0130518. PubMed ID: 26110267
[TBL] [Abstract][Full Text] [Related]
8. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
9. Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.
Gong Q; Wang C; Rohr J; Feldman AL; Chan WC; McKeithan TW
Haematologica; 2016 Jun; 101(6):e269-70. PubMed ID: 27252516
[No Abstract] [Full Text] [Related]
10. Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.
Yoo HY; Kim P; Kim WS; Lee SH; Kim S; Kang SY; Jang HY; Lee JE; Kim J; Kim SJ; Ko YH; Lee S
Haematologica; 2016 Jun; 101(6):e271. PubMed ID: 27252517
[No Abstract] [Full Text] [Related]
11. Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells.
Wijewarnasuriya D; Bebernitz C; Lopez AV; Rafiq S; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):732-742. PubMed ID: 32213625
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness.
Lau E; Kwong G; Fowler TW; Sun BC; Donohoue PD; Davis RT; Bryan M; McCawley S; Clarke SC; Williams C; Banh L; Irby M; Edwards L; Storlie M; Kohrs B; Lilley GWJ; Smith SC; Gradia S; Fuller CK; Skoble J; Garner E; van Overbeek M; Kanner SB
Cytotherapy; 2023 Jul; 25(7):750-762. PubMed ID: 37086241
[TBL] [Abstract][Full Text] [Related]
14. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
15. The landscape of
de Vos L; Grünwald I; Bawden EG; Dietrich J; Scheckenbach K; Wiek C; Zarbl R; Bootz F; Landsberg J; Dietrich D
Epigenetics; 2020 Nov; 15(11):1195-1212. PubMed ID: 32281488
[TBL] [Abstract][Full Text] [Related]
16. The signaling and the metabolic differences of various CAR T cell designs.
Razavi AS; Loskog A; Razi S; Rezaei N
Int Immunopharmacol; 2023 Jan; 114():109593. PubMed ID: 36700773
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
[TBL] [Abstract][Full Text] [Related]
18. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
[TBL] [Abstract][Full Text] [Related]
19. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
Fallarino F; Fields PE; Gajewski TF
J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
[TBL] [Abstract][Full Text] [Related]
20. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]